Analyst firms · H.C. Wainwright · TRVI
H.C. Wainwright TRVI price target and rating history
Trevi Therapeutics Inc. (TRVI) · Health Care
H.C. Wainwright rates Trevi Therapeutics Inc. (TRVI) Buy with a $21 price target, as of its latest action on May 28, 2025. It has published 3 rating actions on TRVI since August 2024, including 0 upgrades and 0 downgrades.
- Current rating
- Buy
- Price target
- $21
- Median target, all firms
- Too few
- Actions on TRVI
- 3
H.C. Wainwright price target on TRVI
Every H.C. Wainwright rating on TRVI
- May 28, 2025
- Dec 12, 2024
- Aug 30, 2024
Questions about H.C. Wainwright and TRVI
- What is H.C. Wainwright's price target for TRVI?
- H.C. Wainwright's latest stated price target for Trevi Therapeutics Inc. (TRVI) is $21, from its action on May 28, 2025.
- What is H.C. Wainwright's rating on TRVI?
- H.C. Wainwright rates TRVI Buy, a bullish rating, as of May 28, 2025.
- When did H.C. Wainwright last change its view on TRVI?
- On May 28, 2025, H.C. Wainwright starts coverage at Buy, price target $21.
More TRVI rating histories
All H.C. Wainwright ratingsTRVI news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.